JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

A multicenter retrospective study of the combination of immune checkpoint inhibitors and chemotherapy regimens with or without liver metastasis for the first-line treatment of advanced gastric cancer

  • 0Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Therapeutic Advances in Medical Oncology +

|

December 23, 2024

|

December 23, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Liver metastasis does not impact outcomes for advanced gastric cancer patients receiving first-line immune checkpoint inhibitors (ICI). This finding suggests liver involvement does not alter the effectiveness of immunotherapy in this patient group.

Area Of Science

  • Oncology
  • Immunotherapy
  • Gastroenterology

Background

  • Immune checkpoint inhibitors (ICI) improve survival in advanced gastric cancer (AGC).
  • The impact of liver metastasis on ICI efficacy in AGC is not well understood.
  • Liver metastasis may cause systemic immune suppression, potentially affecting treatment outcomes.

Purpose Of The Study

  • To investigate the effect of liver metastasis on the efficacy of first-line ICI treatment in advanced gastric cancer patients.
  • To determine if liver metastasis influences overall survival (OS) and progression-free survival (PFS) in AGC patients undergoing immunotherapy.

Main Methods

  • Retrospective analysis of 162 human epidermal growth factor receptor 2 (Her 2)-negative AGC patients receiving first-line immunotherapy and chemotherapy.
  • Patients were categorized into liver metastasis (LM) and no liver metastasis (NLM) groups.
  • Kaplan-Meier method and Cox proportional hazards regression were used to analyze OS and PFS.

Main Results

  • No statistically significant difference in median overall survival (OS) between the LM group (17 months) and NLM group (15 months) (p=0.29).
  • No significant difference in median progression-free survival (PFS) was observed between the two groups (p=0.65).
  • The presence of liver metastasis did not impact survival outcomes in this cohort.

Conclusions

  • Liver metastasis does not significantly affect the prognosis of advanced gastric cancer patients treated with first-line immune checkpoint inhibitors.
  • These findings suggest that liver involvement should not be a deterrent for initiating ICI therapy in AGC.
  • Further research may explore specific mechanisms or patient subgroups where liver metastasis could play a role.

Keywords: